Equities research analysts expect Endo International plc (NASDAQ:ENDP) (TSE:ENL) to announce $648.54 million in sales for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Endo International’s earnings, with the highest sales estimate coming in at $689.20 million and the lowest estimate coming in at $637.59 million. Endo International reported sales of $764.80 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 15.2%. The company is scheduled to announce its next earnings report after the market closes on Thursday, February 25th.
On average, analysts expect that Endo International will report full-year sales of $2.80 billion for the current fiscal year, with estimates ranging from $2.78 billion to $2.83 billion. For the next financial year, analysts expect that the company will post sales of $2.76 billion, with estimates ranging from $2.60 billion to $2.94 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Endo International.
ENDP has been the subject of several recent analyst reports. Zacks Investment Research downgraded Endo International from a “buy” rating to a “sell” rating and set a $7.50 price target for the company. in a research note on Tuesday, January 12th. Citigroup upped their price target on Endo International from $7.00 to $9.00 in a research note on Tuesday, January 19th. SVB Leerink reiterated a “market perform” rating on shares of Endo International in a research note on Monday, February 8th. Piper Sandler upped their price target on Endo International from $6.00 to $12.00 and gave the stock an “overweight” rating in a research note on Monday, January 4th. Finally, Morgan Stanley upped their price target on Endo International from $3.00 to $4.00 and gave the stock an “underweight” rating in a research note on Thursday, November 12th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. Endo International presently has a consensus rating of “Hold” and a consensus price target of $6.92.
A number of institutional investors have recently bought and sold shares of the business. Rhumbline Advisers raised its holdings in Endo International by 7.8% in the 4th quarter. Rhumbline Advisers now owns 592,188 shares of the company’s stock valued at $4,252,000 after acquiring an additional 42,676 shares in the last quarter. New York State Teachers Retirement System raised its holdings in shares of Endo International by 2.4% in the 4th quarter. New York State Teachers Retirement System now owns 321,383 shares of the company’s stock worth $2,308,000 after buying an additional 7,500 shares in the last quarter. Comerica Bank raised its holdings in shares of Endo International by 11.0% in the 3rd quarter. Comerica Bank now owns 231,916 shares of the company’s stock worth $1,343,000 after buying an additional 22,946 shares in the last quarter. Hunter Associates Investment Management LLC raised its holdings in shares of Endo International by 13.3% in the 4th quarter. Hunter Associates Investment Management LLC now owns 192,575 shares of the company’s stock worth $1,383,000 after buying an additional 22,600 shares in the last quarter. Finally, Jackson Creek Investment Advisors LLC acquired a new position in shares of Endo International in the 4th quarter worth approximately $1,323,000. 79.98% of the stock is owned by hedge funds and other institutional investors.
ENDP stock traded down $0.75 during mid-day trading on Thursday, hitting $9.80. The stock had a trading volume of 241,254 shares, compared to its average volume of 4,444,833. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of -15.51 and a beta of 1.41. The company has a fifty day moving average of $8.09 and a 200 day moving average of $5.36. Endo International has a 1-year low of $2.08 and a 1-year high of $10.89.
About Endo International
Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; TESTOPEL, an implantable pellet indicated for TRT in conditions; EDEX to treat erectile dysfunction; and LIDODERM a topical patch product containing lidocaine.
Further Reading: How to interpret the current ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.